Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31188312 | 0.88 | KIF11 (0.44) | GAANR1H2MAPTCA12CA1 | |
| SCHEMBL14505214 | 0.87 | GAA (0.40) | GAAALDH1A1NR1H2NR1H4MAPT | |
| SCHEMBL591090 | 0.83 | CES2 (0.55) | GAAALDH1A1MAPTNR3C2CES2 | |
| SCHEMBL1186570 | 0.81 | GAA (0.67) | GAAALDH1A1NR1H2NR1H4MAPT | |
| SCHEMBL3288448 | 0.81 | ADRB2 (0.52) | GAAALDH1A1NR1H2NR1H4MAPT | |
| SCHEMBL17374982 | 0.81 | EGFR (0.47) | ALDH1A1MAPTESR2LMNACA12 | |
| SCHEMBL14859967 | 0.81 | PDK2 (0.41) | ALDH1A1MAPTNR3C2CES2CES1 | |
| SCHEMBL364243 | 0.81 | GAA (0.66) | GAAALDH1A1MAPTKDM4ECRBN | |
| SCHEMBL7987024 | 0.81 | GAA (0.44) | GAAALDH1A1NR1H2NR1H4MAPT | |
| SCHEMBL17253286 | 0.81 | CA1 (0.40) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725944-A1 | NEW METHOD FOR PREPARING OXOPYRIDINE COMPOUND, AND KEY INTERMEDIATE AND USE | Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| CN-116262736-B | Novel oxo-pyridine compound and preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-115066417-B | Factor XIa inhibitors | 上海京新生物医药有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-116283750-B | Heterocyclic amide derivative and preparation method and application thereof | 成都泰和伟业生物科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-12195490-B2 | STRAD-binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2024251276-A1 | NEW METHOD FOR PREPARING OXOPYRIDINE COMPOUND, AND KEY INTERMEDIATE AND USE | 成都施贝康生物医药科技有限公司 | 2024-12-12 | — | — | WO | disclosed |
| CN-117800955-A | 2-or 4-pyrone derivative, pharmaceutical composition, preparation method and application thereof | 上海美悦生物科技发展有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-116969918-A | Fluoro substituted pyridone derivative and its pharmaceutical composition, preparation method and use | 上海美悦生物科技发展有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116874387-A | Novel preparation method of oxo-pyridine compound and key intermediate | 成都施贝康生物医药科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-5955463-A | ANTITUMOR, ANTIINFLAMMATORY, AND ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 1999-09-21 | — | — | US | disclosed |
| WO-1999037630-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | VERSICOR, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999001442-A1 | TRIAZINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ZENECA LIMITED (GB) | 1999-01-14 | — | — | WO | disclosed |
| US-5843942-A | Aromatic amino ethers as pain relieving agents | ZENECA LIMITED (GB) | 1998-12-01 | — | — | US | disclosed |
| US-5444061-A | Antitumor agents | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-08-22 | — | — | US | disclosed |
| US-5395838-A | Aromatic aminomethyl substitutes compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-03-07 | — | — | US | disclosed |
| US-5280027-A | Quinazoline containing compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-18 | — | — | US | disclosed |
| US-5252573-A | Quinazoline derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-12 | — | — | US | disclosed |
| WO-1992016512-A1 | ANTI-CANCER COMPOUNDS | BRITISH TECHNOLOGY GROUP PLC (GB) | 1992-10-01 | — | — | WO | disclosed |
| US-5089499-A | Anticarcinogenic agents; thymidylate synthetase inhibitors; antiallergens; psoriasis | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | SLC10A1, HNMT, OGFR | GAA 664/4885ALDH1A1 317/4885NR1H2 427/4885 |
| US-12195490-B2 | STRAD-binding agents and uses thereof | STRAP, STRA6, PLAUR | GAA 1155/4885ALDH1A1 3678/4885NR1H2 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.